HK1060981A1 - External preparations for treating dermatitis - Google Patents

External preparations for treating dermatitis

Info

Publication number
HK1060981A1
HK1060981A1 HK04104106A HK04104106A HK1060981A1 HK 1060981 A1 HK1060981 A1 HK 1060981A1 HK 04104106 A HK04104106 A HK 04104106A HK 04104106 A HK04104106 A HK 04104106A HK 1060981 A1 HK1060981 A1 HK 1060981A1
Authority
HK
Hong Kong
Prior art keywords
weight
medicine
treating dermatitis
external preparations
cyclodextrin
Prior art date
Application number
HK04104106A
Other languages
English (en)
Inventor
Hajime Yamada
Akira Yamada
Original Assignee
Cac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cac Corp filed Critical Cac Corp
Publication of HK1060981A1 publication Critical patent/HK1060981A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK04104106A 2002-06-03 2004-06-09 External preparations for treating dermatitis HK1060981A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002161000 2002-06-03

Publications (1)

Publication Number Publication Date
HK1060981A1 true HK1060981A1 (en) 2004-09-03

Family

ID=29706567

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104106A HK1060981A1 (en) 2002-06-03 2004-06-09 External preparations for treating dermatitis

Country Status (14)

Country Link
US (1) US7897161B2 (ja)
EP (1) EP1512404B1 (ja)
JP (1) JP3820577B2 (ja)
KR (1) KR100647857B1 (ja)
CN (1) CN1219520C (ja)
AT (1) ATE446096T1 (ja)
AU (1) AU2002355005B2 (ja)
CA (1) CA2488011C (ja)
DE (1) DE60234132D1 (ja)
DK (1) DK1512404T3 (ja)
ES (1) ES2356370T3 (ja)
HK (1) HK1060981A1 (ja)
TW (1) TWI278318B (ja)
WO (1) WO2003101460A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005053841A (ja) * 2003-08-05 2005-03-03 Kyouto Biomedical Science:Kk 皮膚外用剤
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
US7919250B2 (en) * 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
US7854936B2 (en) 2008-01-14 2010-12-21 Active Organics, Inc. Anti-inflammatory hydrolysate of C. versicolor
JP5456802B2 (ja) * 2012-01-23 2014-04-02 株式会社Ｃａｃ 細胞遊走促進剤及び創傷治療用の経皮吸収剤
ITMI20122002A1 (it) * 2012-11-26 2014-05-27 Farmacologico Milanese Srl Lab Preparazioni farmaceutiche liquide stabilizzate
CA2931862C (en) 2013-11-08 2024-01-23 Carlos Filipe Method of stabilizing molecules without refrigeration using water soluble polymers and applications thereof in performing chemical reactions
EP4122469A1 (en) * 2014-03-28 2023-01-25 Paul Maes Composition comprising cyclodextrin and budesonide derivatives for the treatment and prophylaxis of pulmonary inflammations
AU2015410635B2 (en) * 2015-09-29 2021-08-19 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
KR102071614B1 (ko) 2019-04-30 2020-01-30 김민청 6-디아조-5-옥소-l-노르루신을 포함하는 염증성 피부 질환 치료용 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5799M (ja) 1966-03-22 1968-03-25
US3859436A (en) 1968-10-02 1975-01-07 Kolmar Laboratories Sugar composition for topical application
US3777597A (en) 1970-04-29 1973-12-11 Pharmachem Corp Method of shaving employing an aqueous solution of dextran
US5547997A (en) * 1991-10-01 1996-08-20 Chemisches Laboratorium Dr. Kurt Richter Gmbh Plant-derived cosmetic composition and method of treatment of skin
GB9211736D0 (en) * 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
FR2719772B1 (fr) * 1994-05-11 1996-08-02 Goemar Lab Sa Composition cosmétique ou pharmaceutique, notamment dermatologique contenant de la laminarine ou des oligosaccharides dérivés de laminarine.
JP2920611B2 (ja) * 1995-12-11 1999-07-19 株式会社シーエーシー 皮膚炎の治療外用剤
JPH1025240A (ja) * 1996-04-09 1998-01-27 Dokutaazu Kosumeteikusu:Kk 浴用剤
JPH09315987A (ja) 1996-05-24 1997-12-09 Kureha Chem Ind Co Ltd 泡盛の抗アレルギー有効成分としての利用
DE19710368A1 (de) * 1997-03-13 1998-09-17 Henkel Kgaa Verwendung von wasserlöslichen beta-Glucanen als Wirkstoffe zur Herstellung von therapeutischen Mitteln zur Hautbehandlung
JPH11180813A (ja) * 1997-12-19 1999-07-06 Ichimaru Pharcos Co Ltd 海藻抽出物含有抗菌・防腐剤
AU3657100A (en) * 1999-03-12 2000-10-04 Biotec Asa Use of water-soluble beta-(1,3) glucans as agents for producing therapeutic skintreatment agents
US20030130248A1 (en) * 2000-05-31 2003-07-10 Mozzone Keith C. Topical anti-inflammatory compositions
JP2002114670A (ja) 2000-10-02 2002-04-16 Noevir Co Ltd 抗菌性皮膚外用剤
JP2002060314A (ja) 2001-09-18 2002-02-26 Hakuto Co Ltd 皮膚外用剤

Also Published As

Publication number Publication date
US7897161B2 (en) 2011-03-01
EP1512404B1 (en) 2009-10-21
AU2002355005B2 (en) 2006-04-13
KR100647857B1 (ko) 2006-11-23
EP1512404A4 (en) 2006-04-12
US20050175640A1 (en) 2005-08-11
DE60234132D1 (de) 2009-12-03
CA2488011C (en) 2008-02-12
DK1512404T3 (da) 2010-01-04
JP3820577B2 (ja) 2006-09-13
CA2488011A1 (en) 2003-12-11
CN1219520C (zh) 2005-09-21
KR20050016479A (ko) 2005-02-21
AU2002355005A1 (en) 2003-12-19
WO2003101460A1 (fr) 2003-12-11
TW200307552A (en) 2003-12-16
ES2356370T3 (es) 2011-04-07
CN1466952A (zh) 2004-01-14
JPWO2003101460A1 (ja) 2005-09-29
TWI278318B (en) 2007-04-11
ATE446096T1 (de) 2009-11-15
EP1512404A1 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
HK1060981A1 (en) External preparations for treating dermatitis
Kieliszek et al. Selenium supplementation in the prevention of coronavirus infections (COVID-19)
WO2005087920A3 (en) Recombinant chondroitinase abc i and uses thereof
WO1995014028A3 (en) Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
EP2045270A3 (en) Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
EP1713505B1 (en) Method of preparation of a fungal glucane hydrogel having antibacterial and immunostimulant activity, and use thereof
Gupta et al. Comparative analysis of dietary fiber activities of enzymatic and gamma depolymerized guar gum
Nagasawa et al. Enhancement of plant growth stimulation activity of irradiated alginate by fractionation
KR970032871A (ko) 피부염의 치료외용제
TW200745154A (en) Oligosaccharides derived from fucoidan
CN109966110B (zh) 一种智能拉筋床
ATE325627T1 (de) Therapeutische zubereitungen enthaltend modifizierte polysaccharide
PL375088A1 (en) Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation
CA2424830A1 (en) Composition comprising fucose and vitamin c and/or vitamin a
NO20081415L (no) Fremgangsmate for utforelse av en perkutan koronar intervensjon
WO2003070185A3 (en) Method for treating cellulite
Poposka et al. P1495ECG parameters as predictors of response to cardiac resynchronization therapy
Nagasawa et al. Suppression of Zn stress on barley by irradiated chitosan
Puymirat et al. 009: Comparison of bleeding complications and three-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction. The FAST-MI registry
WO2003013498A3 (de) Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen
Vasse et al. High Frequency of ANTI-Platelet Factor 4/Heparin Antibodies in Patients with LUNG Transplantation
CHAMURA et al. Studies on the Relation between the Tolerance of Crops to Soil Acidity and That to Low pH:(10) On the uptake of K-ion in passive and active processes

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220306